乳腺肿瘤中与BRCA2突变相关的极光激酶A扩增。

Aurora-A amplification associated with BRCA2 mutation in breast tumours.

作者信息

Bodvarsdottir Sigridur K, Hilmarsdottir Holmfridur, Birgisdottir Valgerdur, Steinarsdottir Margret, Jonasson Jon G, Eyfjord Jorunn E

机构信息

Icelandic Cancer Society, Skogarhlid 8, 105 Reykjavik, Iceland; University of Iceland, Department of Medicine, Vatnsmyrarvegi 16, 101 Reykjavik, Iceland.

出版信息

Cancer Lett. 2007 Apr 8;248(1):96-102. doi: 10.1016/j.canlet.2006.06.003. Epub 2006 Jul 24.

DOI:10.1016/j.canlet.2006.06.003

PMID:16860930

Abstract

Potential interaction of Aurora-A amplification and BRCA2 mutation was examined in breast tumours from BRCA2 999del5 mutation carriers (n=20) and non-carriers (n=41). Aurora-A amplification studied by FISH was significantly more common in breast tumours from BRCA2 mutation carriers (p=0.0005). Extensive Aurora-A amplification was also detected on metaphase chromosomes in three breast epithelial cell lines with the same BRCA2 mutation. In addition, significant association was found between Aurora-A amplification and TP53 mutations in non-BRCA2 mutation carrier tumours (p=0.007). These results suggest that breast tumours with mutations in BRCA2 or TP53 could be promising candidates for Aurora-A targeted treatment.

摘要

在携带BRCA2 999del5突变的乳腺癌患者（n = 20）和非携带者（n = 41）的乳腺肿瘤中，检测了Aurora-A扩增与BRCA2突变之间的潜在相互作用。通过荧光原位杂交（FISH）研究发现，Aurora-A扩增在携带BRCA2突变的乳腺肿瘤中明显更为常见（p = 0.0005）。在具有相同BRCA2突变的三个乳腺上皮细胞系的中期染色体上，也检测到广泛的Aurora-A扩增。此外，在非BRCA2突变携带者的肿瘤中，发现Aurora-A扩增与TP53突变之间存在显著关联（p = 0.007）。这些结果表明，BRCA2或TP53发生突变的乳腺肿瘤可能是Aurora-A靶向治疗的理想候选对象。